BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Institute For Diabetes Discovery, L.L.C. (IDD) Release: Highly Selective Aldose Reductase Inhibitors For Diabetes Complications Announced


10/19/2005 5:08:50 PM

BRANFORD, Conn., June 28 /PRNewswire/ -- The Institute for Diabetes Discovery, LLC (IDD) has presented data on the most selective Aldose Reductase Inhibitors (ARIs) ever developed for reducing the impact of diabetic peripheral neuropathy (DPN), according to a recent report from The American Chemical Society's national meeting.

As part of its aldose reductase inhibitor program, IDD produced several series of inhibitors that led to the discovery of lidorestat, which has advanced to phase 2 clinical trials. More recently, IDD focused its efforts on next generation ARIs with an emphasis on enhanced efficacy, desirable pharmacokinetic properties and greater selectivity. The result has been the discovery and development of a novel series of potent compounds that are orally active, (IC50 < 10 nM), and extremely selective (>25,000:1) for aldose reductase versus aldehyde reductase, a closely related enzyme with a beneficial physiological role. IDD's new compounds are all aimed at slowing the progress of diabetic complications, particularly peripheral neuropathy. These new compounds have significantly improved the motor nerve conduction velocity by 69% to 85% in an STZ-induced model. IDD compounds also lower sciatic nerve sorbitol levels (ED50 = 0.6 - 2.5 mg/kg/d) and are highly bioavailable (79 - 97%).

While recent scientific evidence has confirmed the effectiveness of ARI therapy in treating DPN, the development of this class of drugs has been hindered by negative side effects, many of which are attributed to a lack of selectivity. About 17 million people in the United States have been diagnosed with diabetes, and it is estimated that 50% have some degree of peripheral neuropathy. The total annual cost incurred by all payers in treating people with DPN and associated complications is approximately $11 billion.

According to Professor Paul Zimmet, Chairman of the IDD Scientific Advisory Board and Director of the International Diabetes Institute in Melbourne, Australia, "What AIDS was in the last 20 years of the 20th Century, diabetes and its complications will be in the first 20 years of this century. The discovery of drugs to address the neuropathic complications of diabetes is a very important initiative in attacking the devastation that diabetes causes to both individuals and society."

IDD is a biopharmaceutical company specializing in the discovery and preclinical development of small-molecule drugs for the prevention and treatment of obesity and diabetes and its complications. IDD is a division of The Institutes for Pharmaceutical Discovery, LLC, a privately held pharmaceutical company located in Branford, Connecticut.

The Institute for Diabetes Discovery, LLC

CONTACT: Nils Bergenhem, Vice President of Research, The Institute forDiabetes Discovery, LLC, +1-203-315-4000


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->